| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 |
Lupin
2,072.90
+1.50
(0.07%)
There are 8 new updates from the company19 hours ago
Show All
Market Cap
94,636.37 Cr
EPS
42.05
PE Ratio
32.98
Dividend Yield
0.39 %
Industry
Healthcare52 Week High
2,402.90
52 Week Low
1,493.30
PB Ratio
6.05
Debt to Equity
0.28
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from31 analysts
Company News
View All News
Lupin Ltd: FDA Approval for Rivaroxaban Tablets and Strong Q4 ResultsToday
Lupin received USFDA approval for Rivaroxaban Tablets in 10 mg, 15 mg, and 20 mg strengths. Q4 revenue increased 12.2% YoY to ₹5,567.1 crore, with profit surging 121.1% to ₹794.86 crore. US sales reached $245 million, up from $209 million last year.
Lupin Receives FDA Approval for RivaroxabanToday
Lupin has obtained approval from the U.S. Food and Drug Administration (FDA) for Rivaroxaban, a medication with annual U.S. sales of approximately $8 billion.
Lupin Ltd: Q4 Revenue and EBITDA Meet Expectations, North America Leads GrowthToday
Lupin Ltd reported Q4 FY2025 results with revenue up 12.2% YoY to ₹5,567.1 crore, EBITDA up 22.5% YoY to ₹996.85 crore, and profit up 121.1% YoY to ₹794.86 crore. North American sales grew to ₹2,261.8 crore, leading overall growth. US sales reached $245 million, up from $209 million last year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,740.10 | #1 4,17,508.28 | 34.74 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 48.47 | |
6,214.50 | 1,64,975.45 | 79.65 | 8,184.00 | 0.89 | 1,600 | 64.53 | 60.71 | |
1,502.20 | 1,21,319.92 | 22.91 | 26,520.70 | 14.17 | 4,155 | 30.28 | 49.89 | |
3,265.00 | 1,10,502.44 | 58.94 | 10,785.70 | 11.59 | 1,656 | 13.54 | 52.68 | |
2,559.90 | 1,05,615.98 | 51.56 | 10,615.60 | 19.57 | 1,942 | -16.38 | 58.84 | |
1,236.30 | 1,03,163.72 | #1 18.00 | 28,905.40 | 12.36 | 5,578 | 21.14 | 65.96 | |
2,072.90 | #7 94,636.37 | #5 32.98 | #5 20,141.50 | #1 19.94 | #7 1,936 | #1 112.49 | 53.31 | |
904.70 | 91,033.99 | 20.06 | 19,831.50 | 13.82 | 3,831 | 29.92 | 57.43 | |
1,216.90 | 70,677.75 | 20.09 | 29,559.20 | 17.55 | 3,169 | -10.04 | 54.53 | |
30,330.00 | 64,449.13 | 48.33 | 6,097.20 | 10.80 | 1,201 | 16.01 | 51.70 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
19.94 %
Net Income Growth
332.34 %
Cash Flow Change
92.30 %
ROE
277.31 %
ROCE
143.65 %
EBITDA Margin (Avg.)
75.22 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 |
| Total Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 May 2025 |  Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 16 Jul 2024 |  Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 28 Jul 2021 | Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
Announcements
Announcement under Regulation 30 (LODR)-Investor Presentation
55 minutes ago
55 minutes agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release1 hour ago
1 hour agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 hours ago
4 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release19 hours ago
19 hours agoCorporate Action-Board approves Dividend19 hours ago
19 hours agoAnnouncement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association19 hours ago
19 hours agoAppointment Of M/S. Makarand M. Joshi & Co. Company Secretaries As Secretarial Auditors Of The Company For A Term Of Five Consecutive Years.19 hours ago
19 hours agoAnnouncement under Regulation 30 (LODR)-Change in Directorate19 hours ago
19 hours agoBoard Meeting Outcome for Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 202519 hours ago
19 hours agoApproval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 202519 hours ago
19 hours agoApproval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 202520 hours ago
20 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 02, 2025
May 02, 2025Updates On Transfer Of Companys API R&D Division And Over-The-Counter Consumer Healthcare Business On Slump Sale Basis.Apr 30, 2025
Apr 30, 2025Board Meeting Intimation for Considering And Taking On Record Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2025 And Recommend Dividend If Any.Apr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025The Company Has Informed The Exchange About Court Order In The Matter Of A Patent Case.Apr 16, 2025
Apr 16, 2025Rumour verification - Regulation 30(11)Apr 16, 2025
Apr 16, 2025Clarification sought from Lupin LtdApr 16, 2025
Apr 16, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 07, 2025
Apr 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Apr 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-RestructuringMar 31, 2025
Mar 31, 2025Announcement under Regulation 30 (LODR)-RestructuringMar 31, 2025
Mar 31, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On March 31 2025.Mar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 21, 2025
Mar 21, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 21, 2025
Mar 21, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 20, 2025
Mar 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Mar 20, 2025Incorporation Of A Wholly Owned Subsidiary.Mar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2025
Mar 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Feb 19, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Feb 12, 2025Technical Indicators
RSI(14)
Neutral 53.16
ATR(14)
Less Volatile 71.27
STOCH(9,6)
Neutral 49.07
STOCH RSI(14)
Neutral 52.30
MACD(12,26)
Bullish 0.36
ADX(14)
Weak Trend 10.04
UO(9)
Bearish 51.68
ROC(12)
Downtrend And Accelerating -1.61
WillR(14)
Neutral -35.45
About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
